• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用 MHC 差异建立小鼠骨髓移植(BMT)模型模拟急性移植物抗宿主病(aGVHD)。

Modeling acute graft-versus-host disease (aGVHD) in murine bone marrow transplantation (BMT) models with MHC disparity.

机构信息

University Medical Center Ulm, Department of Pediatrics and Adolescent Medicine, Ulm, Germany.

University Ulm, Institute of Pathology, Ulm, Germany.

出版信息

Methods Cell Biol. 2022;168:19-39. doi: 10.1016/bs.mcb.2021.12.007. Epub 2022 Jan 10.

DOI:10.1016/bs.mcb.2021.12.007
PMID:35366982
Abstract

For more than 50years, hematopoietic stem cell transplantation (HSCT) has been the major curative therapy for hematological malignancies and genetic disorders, but its success is limited by the development of graft-versus-host disease (GVHD). GVHD represents a post-transplantation disorder representing the immune-mediated attack of transplant-derived T cells against recipient tissue finally leading to increased morbidity and mortality of the recipient. GVHD develops if donor and recipient are disparate in major or minor histocompatibility antigens (MHC, miHA). Most of the initial knowledge about the biology of GVHD is derived from murine bone marrow transplantation (BMT) models. Of course, GVHD mouse models do not reflect one to one the human situation, but they contribute significantly to our understanding how conditioning and danger signals activate the immune system, enlighten the role of individual molecules, e.g., cytokines, chemokines, death-inducing ligands, define the function of lymphocytes subpopulations for GVHD development and have significant impact on establishing new treatment and prevention strategies used in clinical HSCT. This chapter describes in detail the procedure of allogeneic BMT and the development of GVHD in two commonly used allogeneic murine BMT models (B6→B6.bm1, B6→B6D2F1) with different MHC disparities, which can be used as a basis for advanced studies of GVHD pathology or the development of new treatment strategies.

摘要

50 多年来,造血干细胞移植(HSCT)一直是治疗血液系统恶性肿瘤和遗传疾病的主要方法,但由于移植物抗宿主病(GVHD)的发展,其成功率受到限制。GVHD 是一种移植后疾病,代表移植来源的 T 细胞对受者组织的免疫介导攻击,最终导致受者发病率和死亡率增加。如果供体和受体在主要或次要组织相容性抗原(MHC、miHA)上存在差异,则会发生 GVHD。关于 GVHD 生物学的大部分初始知识来自于小鼠骨髓移植(BMT)模型。当然,GVHD 小鼠模型不能一一反映人类的情况,但它们极大地促进了我们对如何调节和危险信号激活免疫系统的理解,阐明了单个分子(例如细胞因子、趋化因子、诱导死亡配体)的作用,定义了淋巴细胞亚群在 GVHD 发展中的功能,并对建立用于临床 HSCT 的新治疗和预防策略产生了重大影响。本章详细描述了两种常用的异基因小鼠 BMT 模型(B6→B6.bm1、B6→B6D2F1)中异基因 BMT 和 GVHD 发展的过程,这些模型具有不同的 MHC 差异,可以作为 GVHD 病理学的高级研究或新治疗策略的发展的基础。

相似文献

1
Modeling acute graft-versus-host disease (aGVHD) in murine bone marrow transplantation (BMT) models with MHC disparity.利用 MHC 差异建立小鼠骨髓移植(BMT)模型模拟急性移植物抗宿主病(aGVHD)。
Methods Cell Biol. 2022;168:19-39. doi: 10.1016/bs.mcb.2021.12.007. Epub 2022 Jan 10.
2
Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.用于鉴定血液系统恶性肿瘤中T细胞识别的肿瘤抗原的策略,以改善异基因血液和骨髓移植后的移植物抗肿瘤反应。
Biol Blood Marrow Transplant. 2015 Jun;21(6):1000-7. doi: 10.1016/j.bbmt.2014.11.001. Epub 2014 Nov 20.
3
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
4
Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.预防性供体白细胞输注对接受非清髓性预处理和异基因骨髓移植治疗的晚期血液系统恶性肿瘤患者混合嵌合体、移植物抗宿主病及抗肿瘤反应的影响
Biol Blood Marrow Transplant. 2003 May;9(5):320-9. doi: 10.1016/s1083-8791(03)00077-6.
5
Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.嵌合体与免疫耐受:从弗里马丁牛和新生小鼠到人类
Hum Immunol. 1997 Feb;52(2):155-61. doi: 10.1016/S0198-8859(96)00290-X.
6
Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.通过第三方异基因供体进行骨髓移植实现已确立的移植物抗宿主病的缓解。
Exp Hematol. 2008 Sep;36(9):1216-25. doi: 10.1016/j.exphem.2008.03.018. Epub 2008 Jul 2.
7
Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.异基因骨髓移植后给予白细胞介素-7可改善免疫重建,而不会加重移植物抗宿主病。
Blood. 2001 Oct 1;98(7):2256-65. doi: 10.1182/blood.v98.7.2256.
8
Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.骨髓移植后延迟输注免疫活性供体细胞可打破移植物抗宿主耐受性,从而实现持续的抗白血病反应且无严重移植物抗宿主病。
Blood. 1995 Jun 1;85(11):3302-12.
9
Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.移植前预处理和供体T细胞对骨髓移植后嵌合状态、移植物抗宿主病、移植物抗白血病反应及耐受性的影响。
Blood. 1991 Jun 1;77(11):2515-23.
10
Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene.使用表达胸苷激酶自杀基因的供体T细胞对骨髓移植后的同种异体反应进行调控。
Leuk Lymphoma. 2002 Oct;43(10):2011-6. doi: 10.1080/1042819021000016041.

引用本文的文献

1
Minor histocompatibility antigens HA-8 and PANE1 in the TUNISIAN population.在突尼斯人群中,次要组织相容性抗原 HA-8 和 PANE1。
Mol Genet Genomic Med. 2022 Nov;10(11):e2050. doi: 10.1002/mgg3.2050. Epub 2022 Aug 29.